<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Principles of antimicrobial therapy of Pseudomonas aeruginosa infections</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Souha S Kanj, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen B Calderwood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Pseudomonas aeruginosa</em> is a key gram-negative aerobic bacillus in the differential diagnosis of a number of infections. This organism is important because it is often antibiotic resistant and can cause severe hospital-acquired infections associated with a high mortality rate, especially in immunocompromised hosts.</p><p>The principles of antimicrobial treatment of infections caused by <em>P. aeruginosa </em>will be reviewed here. Discussion on the epidemiology, pathogenesis, clinical manifestations, diagnosis, and treatment of specific types of pseudomonal infections can be found elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3148.html" rel="external">"Pseudomonas aeruginosa infections of the eye, ear, urinary tract, gastrointestinal tract, and central nervous system"</a>.)</p><p></p><p>Treatment issues related to <em>P. aeruginosa</em> lung infection in patients with cystic fibrosis are also discussed separately. (See  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Pseudomonas aeruginosa'</a> and  <a class="medical medical_review" href="/d/html/140721.html" rel="external">"Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">GENERAL PRINCIPLES OF TREATMENT</span><span class="headingEndMark"> — </span>The following principles apply to the management of <em>P. aeruginosa</em> infections:</p><p class="bulletIndent1"><span class="glyph">●</span>The risk of antibiotic resistance, both intrinsic and acquired, is an important consideration when selecting empiric or directed therapy. (See <a class="local">'Antimicrobial resistance'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monotherapy is generally adequate, although combination therapy is indicated in certain high-risk patients and in severe infections. (See <a class="local">'Role of combination antimicrobial therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prompt initiation of antimicrobial therapy is important, as delayed therapy correlates with increased mortality.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Source control is important. For example, infected catheters and other implanted devices should be removed, abscesses should be drained, and obstructions should be relieved.</p><p></p><p class="headingAnchor" id="H6674788"><span class="h1">ANTIMICROBIAL RESISTANCE</span><span class="headingEndMark"> — </span><em>P. aeruginosa</em> is intrinsically resistant to numerous antibiotics and can acquire resistance to other agents during therapy. Some strains are multidrug resistant (ie, they are resistant to three or more classes of antibiotics) [<a href="#rid1">1</a>]. These features limit the choices of antibiotics for <em>P. aeruginosa</em>. </p><p class="headingAnchor" id="H632998993"><span class="h2">Definitions</span><span class="headingEndMark"> — </span>A joint initiative by the European Centre for Disease Prevention and Control (ECDC) and the United States Centers for Disease Control and Prevention (CDC) in 2011 proposed specific definitions for characterizing drug resistance in organisms that cause many health care-associated infections [<a href="#rid2">2</a>]. The following definitions were established, based on the extent of resistance to antibiotic classes to which <em>Pseudomonas</em> does not have intrinsic resistance (<a class="graphic graphic_table graphicRef109975" href="/d/graphic/109975.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidrug-resistant</strong> – Isolate is non-susceptible to at least one agent in three or more antibiotic classes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extensively drug-resistant</strong> – Isolate is non-susceptible to at least one agent in all but two or fewer antibiotic classes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pandrug-resistant</strong> – Isolate is non-susceptible to all agents.</p><p></p><p class="headingAnchor" id="H632999029"><span class="h2">Epidemiology of resistance</span><span class="headingEndMark"> — </span>The global burden of antimicrobial resistance in clinical isolates of <em>P. aeruginosa</em> is high. However, national surveillance data should be interpreted with caution because local resistance rates are highly variable and closely linked with local antimicrobial usage patterns and patient type. </p><p>Data collected from over 4500 hospitals in the United States' National Healthcare Safety Network from 2011 to 2014 revealed the following rates of multidrug resistance among <em>P. aeruginosa </em>isolates [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Ventilator-associated pneumonia – 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Central line-associated blood stream infection – 18 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Catheter-associated urinary tract infection – 18 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Surgical site infection – 4 percent</p><p></p><p>A subsequent study analyzing data from 890 hospitals in the United States reported that the rate of multidrug-resistant <em>P. aeruginosa</em> infections among hospitalized patients decreased by 30 percent between 2012 and 2017 (from 13.10 to 9.43 cases per 10,000 hospitalizations) [<a href="#rid4">4</a>].</p><p>Rates of resistance are higher in resource-limited than in resource-rich settings. In a 2010 to 2015 study of <em>P. aeruginosa</em> device-associated bacteremia isolates collected from over 700 intensive care units (ICUs) in 50 resource-limited countries, rates of resistance to <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> and <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> were 30 and 44 percent, respectively [<a href="#rid5">5</a>]. In contrast, corresponding resistance rates in ICUs in the United States were 10 and 26 percent.</p><p>Antimicrobial resistance among <em>P. aeruginosa</em> is associated with increased length of hospitalization and increased mortality [<a href="#rid6">6</a>]. Risk factors for infection with resistant <em>P. aeruginosa</em> isolates include the following [<a href="#rid7">7-11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>ICU stay</p><p class="bulletIndent1"><span class="glyph">●</span>Bedridden status</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of invasive devices</p><p class="bulletIndent1"><span class="glyph">●</span>Prior use of certain antibiotics, including broad-spectrum cephalosporins, aminoglycosides, carbapenems, fluoroquinolones</p><p class="bulletIndent1"><span class="glyph">●</span>Diabetes mellitus</p><p class="bulletIndent1"><span class="glyph">●</span>Surgery</p><p></p><p>Nosocomial outbreaks of resistant pseudomonal infections have been reported in healthcare facilities around the world [<a href="#rid12">12-15</a>]. Outbreaks have also been associated with contaminated medical devices, such as endoscopes and transesophageal probes [<a href="#rid11">11,16</a>]. In 2023, a nation-wide outbreak in the United States of extensively drug-resistant <em>P. aeruginosa</em>, resistant to all antipseudomonal agents including <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> as well as polymixins, was found to be associated with contaminated over-the-counter <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> [<a href="#rid10">10</a>].</p><p>Prior use of carbapenem, including <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a> (which does not have antipseudomonal activity), has been repeatedly identified as a risk factor for carbapenem resistance [<a href="#rid17">17-19</a>]. Additional risk factors include male gender, ICU stay, and urinary bladder catheterization longer than seven days.</p><p>Emergence of antibiotic resistance during therapy for <em>P. aeruginosa </em>infections, resulting in increased rates of morbidity and mortality and higher costs, is a well-known problem. As an example, in a study involving 3393 <em>P. aeruginosa</em> isolates from ICU and non-ICU settings in a tertiary-care center, standard antibiograms were less able to predict susceptibility as the duration of hospitalization increased [<a href="#rid20">20</a>]. Similarly, in an observational study, resistant strains of <em>P. aeruginosa</em> emerged in 10.2 percent of 271 cases during treatment with four individual antipseudomonal agents [<a href="#rid21">21</a>]. <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a> was associated with the lowest risk of emergent resistance, and <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> with the highest risk. Emergence of resistance during therapy is a challenge with newer agents that have activity against <em>Pseudomonas</em>; this issue is discussed elsewhere. (See <a class="local">'Emergence of resistance to novel agents'</a> below.)</p><p>Acquired resistance is mediated by various mechanisms, including degrading enzymes, reduced permeability, and active efflux via mutation or acquisition of exogenous resistance determinants [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/3142.html" rel="external">"Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">ANTIBIOTICS WITH ANTIPSEUDOMONAL ACTIVITY</span><span class="headingEndMark"> — </span>A number of antimicrobial agents have activity against <em>P. aeruginosa</em> isolates (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H5"><span class="h2">Intravenous antibiotics</span></p><p class="headingAnchor" id="H2955814964"><span class="h3">Dosing strategies</span><span class="headingEndMark"> — </span>Due to high levels of intrinsic and acquired resistance among pseudomonal isolates, higher doses of traditional antibiotics are often required to achieve sufficient levels. </p><p>Some beta-lactams are often administered as extended infusions (eg, over two to four hours) to maximize the duration that drug concentrations exceed the minimum inhibitory concentration (MIC) of the organism [<a href="#rid24">24-29</a>]. Although clinical data are limited, administration of prolonged infusions for certain beta-lactams and carbapenems is appropriate, especially for critically ill patients or for isolates with elevated MICs to the agent. (See  <a class="medical medical_review" href="/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p>Dosing for antipseudomonal antibiotics is listed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H1789005747"><span class="h3">Antibiotic options</span><span class="headingEndMark"> — </span>Multiple antibiotics from different classes are available to treat pseudomonal infections. Certain first-line agents are preferred due to extensive clinical experience, clinical trial results, and antibiotic stewardship considerations.</p><p class="headingAnchor" id="H6674980"><span class="h4">First-line agents</span><span class="headingEndMark"> — </span>The following antibiotics, grouped by class, can usually be used alone as single agents if in vitro testing shows they are susceptible. The selection of individual agents from this group depends on factors such as the site of the infection, local resistance rates of <em>P. aeruginosa</em>, prior culture results, the patient's history of allergies, and the agents' availability in the local hospital formulary.</p><p>Dosages for intermittent or prolonged infusion is outlined in the tables (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Antipseudomonal penicillins in combination with a beta-lactamase inhibitor include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">Piperacillin-tazobactam</a> </p><p></p><p class="bulletIndent2">Although <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a> has antipseudomonal activity, the addition of tazobactam inhibits AmpC-type beta-lactamases and results in a lower MIC than piperacillin alone. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ticarcillin-clavulanate (not available in the United States or Canada)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cephalosporins with antipseudomonal activity include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a> </p><p class="bulletIndent2"><span class="glyph">•</span>Cefoperazone (not available in the United States)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">Cefepime</a> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monobactam:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">Aztreonam</a> </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fluoroquinolones:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">Levofloxacin</a> has no advantage over ciprofloxacin for infections due to <em>P. aeruginosa</em> since its additional spectrum of coverage is usually unnecessary and potentially harmful. Levofloxacin is primarily indicated for treatment of respiratory tract infections when additional empiric <em>P. aeruginosa</em> coverage is warranted and in rare situations such as a culture-positive polymicrobial infection that includes susceptible strains of streptococci and <em>P. aeruginosa</em>. We do not advise using other quinolone agents such as moxifloxacin for treatment of <em>P. aeruginosa</em>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Carbapenems:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">Meropenem</a></p><p></p><p class="bulletIndent1">In vitro studies have shown that carbapenem MICs are lower with <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> than with <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> [<a href="#rid30">30</a>]. It is unknown whether this in vitro potency difference translates into any difference in clinical outcomes. However, meropenem is preferred over imipenem because imipenem has a higher propensity to induce resistance during treatment [<a href="#rid21">21</a>]. Nevertheless, all carbapenems have been associated with emergent resistance during therapy; thus we reserve their use for the treatment of <em>P. aeruginosa</em> infections resistant to other agents or in polymicrobial infections.</p><p></p><p class="headingAnchor" id="H2000840910"><span class="h4">Role of aminoglycosides</span><span class="headingEndMark"> — </span>Aminoglycosides (<a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>) are active against <em>P. aeruginosa</em> but are generally not used as single agents because of inadequate clinical efficacy at most sites. As examples, aminoglycosides should not be used as monotherapy for pneumonia because they perform poorly in an acidic environment, and aminoglycosides used as monotherapy for bacteremia are associated with high mortality rates [<a href="#rid31">31</a>]. Instead, aminoglycosides are frequently used in combination with other antibiotics for empiric therapy, pending susceptibility results or for the treatment of select serious infections.</p><p>Aminoglycosides can be used as a single agent for the treatment of lower urinary tract infections (eg, cystitis). </p><p>When using an aminoglycoside as part of therapy for an infection with a high risk of <em>P. aeruginosa</em>, we favor <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> over <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, as it has greater intrinsic antipseudomonal activity; however, it may not be widely available. </p><p>The dosing of aminoglycosides is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/475.html" rel="external">"Dosing and administration of parenteral aminoglycosides"</a>.)</p><p class="headingAnchor" id="H6674996"><span class="h4">Antibiotics reserved for multidrug-resistant isolates</span><span class="headingEndMark"> — </span>Several novel agents have activity against <em>P. aeruginosa</em>, but are generally reserved for serious infections with isolates resistant to other agents because of cost and antibiotic stewardship concerns (and, for polymyxins, because of toxicity) (see <a class="local">'Antibiotic selection'</a> below). Doses are listed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Novel beta-lactam-beta-lactamase inhibitor combinations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a> [<a href="#rid32">32,33</a>]</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a> [<a href="#rid34">34-37</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Novel cephalosporin:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">Cefiderocol</a> [<a href="#rid38">38-40</a>] </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Novel carbapenem-beta-lactamase combination:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="121885" href="/d/drug information/121885.html" rel="external">Imipenem-cilastatin-relebactam</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Polymyxins:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">Polymyxin B</a></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">Colistin</a></p><p></p><p class="bulletIndent1">Polymyxins are generally used as part of a combination regimen when treating <em>Pseudomonas</em> infection. Dosing of <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a> and <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Dosing and administration'</a>.)</p><p></p><p>Other potential therapeutic options are still in development [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H6675185"><span class="h2">Oral antibiotics</span><span class="headingEndMark"> — </span>Fluoroquinolones are the only antibiotic class available as an oral formulation that is reliably active against <em>P. aeruginosa</em>. As with other classes of antibiotics, higher doses of certain fluoroquinolones (eg, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>) are often used to treat <em>Pseudomonas.</em></p><p>For infections due to <em>P. aeruginosa</em> alone, we suggest <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> instead of <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> because levofloxacin's additional spectrum of coverage is usually unnecessary; dosages are found in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>). Prulifloxacin (600 mg once daily) is another oral fluoroquinolone available in some European countries.</p><p>We suggest not using other quinolone agents (eg, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>) for treatment of <em>P. aeruginosa</em>. We also suggest not using <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a> as a single agent due to increased risk of baseline resistance and rapid emergence of resistance while on therapy. </p><p class="headingAnchor" id="H8"><span class="h2">Alternative formulations</span><span class="headingEndMark"> — </span>Certain antipseudomonal antibiotics are also available in inhaled, topical, intravitreal, intraventricular, and impregnated cement formulations for specific indications. </p><p>Inhaled antibiotics with activity against <em>P. aeruginosa</em> are sometimes used as an adjunct to treatment of pneumonia due to drug-resistant <em>P. aeruginosa</em> and to prevent exacerbations of bronchiectasis (eg, in the setting of cystic fibrosis) [<a href="#rid42">42</a>]. Inhaled administration has the theoretic advantage of targeting drug levels to bronchial secretions in patients with pneumonia while reducing potential systemic side effects. (See  <a class="medical medical_review" href="/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a> and  <a class="medical medical_review" href="/d/html/6371.html" rel="external">"Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection", section on 'Inhaled antibiotics'</a> and  <a class="medical medical_review" href="/d/html/129310.html" rel="external">"Bronchiectasis in adults: Maintaining lung health", section on 'Inhaled antibiotics'</a>.)</p><p>Other antibiotic formulations are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3418.html" rel="external">"Bacterial endophthalmitis", section on 'Intravitreal antibiotics'</a> and  <a class="medical medical_review" href="/d/html/7665.html" rel="external">"Prosthetic joint infection: Treatment", section on 'Resection arthroplasty with reimplantation'</a> and  <a class="medical medical_review" href="/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.)</p><p class="headingAnchor" id="H6675458"><span class="h1">ROLE OF COMBINATION ANTIMICROBIAL THERAPY</span><span class="headingEndMark"> — </span>One of the most controversial management questions involves the use of combination versus monotherapy for serious infections due to <em>P. aeruginosa. </em>High-quality data informing the decision are lacking. </p><p class="headingAnchor" id="H3016697"><span class="h2">Empiric combination therapy</span><span class="headingEndMark"> — </span>Combination therapy is used by many clinicians for empiric coverage of known or suspected pseudomonal infections, and is usually discontinued once susceptibility results become available.</p><p class="headingAnchor" id="H2092497271"><span class="h3">Indications</span><span class="headingEndMark"> — </span>We suggest the use of two agents from different classes with in vitro activity against <em>P. aeruginosa</em> for empiric treatment of serious infections known or suspected to be caused by <em>P. aeruginosa</em> when there is high risk of antimicrobial resistance or in hosts for whom inappropriate antibiotic therapy would likely be associated with an especially high mortality. Such circumstances include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>When signs of severe sepsis or septic shock are present</p><p class="bulletIndent1"><span class="glyph">●</span>Neutropenic patients with bacteremia</p><p class="bulletIndent1"><span class="glyph">●</span>Burn patients (who have a high incidence of multidrug-resistant <em>P. aeruginosa</em> infections) with serious infections</p><p class="bulletIndent1"><span class="glyph">●</span>In other settings where the incidence of resistance to the chosen antibiotic class is high (eg, &gt;10 to 15 percent)</p><p></p><p>In other circumstances, empiric treatment using only one antipseudomonal agent is appropriate.</p><p>Our rationale for using empiric combination therapy in the settings listed above is to increase the likelihood that at least one of the agents in the combination is active against the infecting strain of <em>Pseudomonas</em>. Further discussion of the rationale for combination therapy is discussed below. (See <a class="local">'Rationale'</a> below.)</p><p class="headingAnchor" id="H2885665624"><span class="h3">Selection of agents</span><span class="headingEndMark"> — </span>The choice of agents for empiric therapy depends on numerous factors, such as the site and severity of the infection, local resistance rates of <em>P. aeruginosa</em>, prior culture susceptibility results, allergies, and the availability of specific agents in the local hospital formulary.</p><p>If empiric combination therapy is used, two agents with different mechanisms of action should generally be chosen based on prior patient isolates and local resistance rates. In general, we suggest a beta-lactam as the first agent and an aminoglycoside as the second, provided there are no contraindications to the use of either. The role and selection of aminoglycosides is discussed above. (See <a class="local">'Role of aminoglycosides'</a> above.)</p><p>Aminoglycosides should be avoided in patients with renal insufficiency or in those hospitalized in institutions with a high percentage of <em>P. aeruginosa</em> resistant to aminoglycosides. In such cases, we use a fluoroquinolone as a second agent. One study suggested better outcomes when using a fluoroquinolone rather than an aminoglycoside as the second agent [<a href="#rid43">43</a>], but further data are warranted before routinely favoring a fluoroquinolone over an aminoglycoside in this setting.</p><p class="headingAnchor" id="H2261333418"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>For empiric therapy, the rationale for using combination therapy is detailed below:</p><p class="headingAnchor" id="H7734581"><span class="h4">Ensure receipt of an active agent</span><span class="headingEndMark"> — </span>The best rationale for the use of combination therapy is to provide initial broad spectrum of activity when there is risk for multidrug-resistant <em>P. aeruginosa </em>so that if the <em>P. aeruginosa</em> is resistant to one agent, it may be susceptible to the other. Delays in active antimicrobial therapy of <em>P. aeruginosa</em> infections have been associated with increased mortality, and the role of a second agent may thus be to cover possible resistant pathogens when resistance rates to the primary agent are high [<a href="#rid1">1,44-48</a>]. Delay in treatment has been linked to increased mortality even when a patient is considered clinically stable at the time of initial evaluation [<a href="#rid49">49</a>].</p><p>This is a similar rationale to that used to support empiric combination therapy for gram-negative bacillary bacteremia in other settings. (See  <a class="medical medical_review" href="/d/html/3149.html" rel="external">"Gram-negative bacillary bacteremia in adults", section on 'Indications and rationale for combination therapy'</a>.)</p><p>In one retrospective study of patients with ventilator-associated pneumonia due to <em>P. aeruginosa</em>, empiric combination therapy was associated with a higher likelihood that appropriate antibiotic therapy was initially used, although an impact on mortality was not demonstrated [<a href="#rid50">50</a>]. A multinational, retrospective study of 294 episodes of <em>P. aeruginosa</em> bacteremic pneumonia in neutropenic individuals found that appropriate empiric combination therapy was associated with improved overall survival (adjusted hazard ratio [aHR] 0.46; 95% CI 0.27-0.78) [<a href="#rid51">51</a>].</p><p class="headingAnchor" id="H4271720154"><span class="h4">Possible synergistic activity</span><span class="headingEndMark"> — </span>A commonly cited reason for use of combination therapy is the potential for synergistic activity against <em>P. aeruginosa</em> with two agents, which in turn may result in better outcomes than single-drug therapy. However, there is no compelling evidence that two agents offer improved survival outcomes for treating <em>P. aeruginosa</em> infections.</p><p>Data on the use of combination versus single-drug therapy for <em>P. aeruginosa</em> infections are mixed, but overall, the best current evidence suggests that there is no additional benefit of a second active agent [<a href="#rid52">52-62</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 64 randomized trials that compared beta-lactam monotherapy with combination therapy with a beta-lactam and an aminoglycoside for over 7500 immunocompetent patients with sepsis of all-cause (bacteremia did not need to be present), there was no survival advantage with combination therapy [<a href="#rid60">60</a>]. A lack of additional benefit was also observed in the subset of 426 patients with <em>P. aeruginosa</em> infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of two randomized trials and 15 observational studies that included patients with documented gram-negative bacteremia, many of whom were immunocompromised, combination therapy was not associated with a mortality benefit overall [<a href="#rid61">61</a>]. However, among the subgroup of patients with <em>P. aeruginosa</em> bacteremia, there was a mortality benefit associated with combination therapy (odds ratio [OR] 0.50; 95% CI 0.30-0.79). Of note, several of the studies in the meta-analysis used aminoglycosides as a single agent in the monotherapy group, which is considered inadequate therapy [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Observational studies have also not supported an association between empiric or definitive combination therapy (generally with a beta-lactam plus an aminoglycoside or fluoroquinolone) and improved mortality [<a href="#rid62">62,64</a>]. In one study of patients with <em>P. aeruginosa</em> bacteremia, definitive combination therapy was associated with reduced 30-day mortality when <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> was the second agent, but not when <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> was the second agent [<a href="#rid43">43</a>].</p><p></p><p>For the most part, these results are in contrast to a frequently quoted retrospective study analyzing data collected more than 20 years ago, which concluded that combination therapy was associated with a reduced mortality rate compared with monotherapy for <em>P. aeruginosa</em> bacteremia (27 versus 47 percent) [<a href="#rid52">52</a>]. However, questions about the validity of these results have arisen because of a number of methodologic problems, including the lack of randomization, the choice of therapy (which may have been influenced by the severity of illness), and the observation that monotherapy in the majority of patients consisted of an aminoglycoside, which is associated with a mortality as high as 70 to 80 percent when used for the treatment of <em>P. aeruginosa</em> bacteremia [<a href="#rid53">53</a>].</p><p>Although not all studies showed clear evidence for a survival benefit with the use of combination therapy, it is possible that it offers other clinical benefits. As an example, studies comparing combination therapy with monotherapy in pulmonary infections in patients with cystic fibrosis have shown no differences in outcome, but the density of bacteria was lower in the sputum, and the time to the next pulmonary infection requiring hospitalization was more prolonged in patients receiving combination therapy [<a href="#rid65">65,66</a>].</p><p class="headingAnchor" id="H2992500519"><span class="h4">Prevent emergent resistance</span><span class="headingEndMark"> — </span>There is limited clinical evidence evaluating the ability of combination therapy to prevent the emergence of antimicrobial resistance in patients with <em>P. aeruginosa</em> bacteremia. </p><p>Emergence of resistance during therapy for <em>P. aeruginosa</em> infections can occur, resulting in increased rates of morbidity and mortality and higher costs. However, most studies of human <em>P. aeruginosa</em> infections have been underpowered to evaluate whether combination therapy can prevent emergent resistance. An observational study reported that resistant <em>P. aeruginosa</em> emerged in 10.2 percent of 271 cases during treatment with four individual antipseudomonal agents [<a href="#rid21">21</a>]. <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">Ceftazidime</a> was associated with the lowest risk and <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> with the highest risk. Addition of an aminoglycoside did not alter this risk.</p><p>This is in contrast to animal and in vitro studies that have suggested that combination therapy may alter this risk. As an example, combination therapy with two antipseudomonal antimicrobial agents limited the risk of emergence of resistant pseudomonal strains compared with monotherapy in an animal model of pseudomonal peritonitis [<a href="#rid67">67,68</a>]. Additionally, an in vitro study suggested that <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> and <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> might be an effective combination for preventing the emergence of resistance during treatment of <em>P. aeruginosa</em> infections [<a href="#rid69">69</a>].</p><p class="headingAnchor" id="H1897310804"><span class="h4">Drawbacks</span><span class="headingEndMark"> — </span>The main drawbacks to combination therapy include additional cost and toxicity. As an example, in a meta-analysis of 64 randomized trials that compared beta-lactam monotherapy with combination therapy with a beta-lactam and an aminoglycoside for sepsis, combination therapy was associated with a significant increase in nephrotoxicity [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H3016715"><span class="h2">Directed combination therapy</span><span class="headingEndMark"> — </span>Definitive therapy can be tailored to the results of susceptibility tests once they are available. Definitive therapy with a single active agent is appropriate for most infections, as there are no convincing clinical data that demonstrate a mortality benefit to combination therapy. (See <a class="local">'Possible synergistic activity'</a> above and <a class="local">'Prevent emergent resistance'</a> above and <a class="local">'Drawbacks'</a> above.)</p><p>Nevertheless, combination therapy is often used in situations in which the risk of emergent resistance or significant morbidity or mortality is high. For example, combination therapy is often used to treat <em>P. aeruginosa</em> endocarditis and bacteremia in high-risk hosts. (See  <a class="medical medical_review" href="/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a>.)</p><p>Initiation of a second antipseudomonal agent for directed therapy may also be reasonable in infections that initially fail or are slow to respond to a single active agent, although there are few clinical, in vitro, or experimental data to support this practice. </p><p>In light of these uncertainties, we recommend consultation with an expert in treating such infections (when possible) if combination therapy is used for a multidrug-resistant organism. (See <a class="local">'Management of multidrug-resistant organisms'</a> below.)</p><p class="headingAnchor" id="H6675731"><span class="h1">MANAGEMENT OF MULTIDRUG-RESISTANT ORGANISMS</span><span class="headingEndMark"> — </span>Infections due to multidrug-resistance <em>P. aeruginosa</em> are a growing clinical problem and should be managed with the assistance of an expert in the treatment of such infections.</p><p class="headingAnchor" id="H3346649395"><span class="h2">Susceptibility testing</span><span class="headingEndMark"> — </span>For infections due to <em>P. aeruginosa</em> resistant to first-line agents (including <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>, cephalosporins, and carbapenems), we check susceptibility to novel agents, including <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a>, and <a class="drug drug_general" data-topicid="121885" href="/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a>, as well as polymyxins (<a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> or <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a>).</p><p>For patients previously infected with a highly resistant isolate who present with a sepsis-like picture, we suggest repeating antibiotic susceptibility testing for novel agents because emergence of resistance during therapy has been reported. (See <a class="local">'Emergence of resistance to novel agents'</a> below.)</p><p class="headingAnchor" id="H23"><span class="h2">Antibiotic selection</span><span class="headingEndMark"> — </span>For infections due to <em>P. aeruginosa</em> resistant to first-line agents (including <a class="drug drug_general" data-topicid="9775" href="/d/drug information/9775.html" rel="external">piperacillin</a>, cephalosporins, and carbapenems), we suggest monotherapy with either <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> or <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> if the isolate is susceptible to one of these. If neither of these can be used, <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a> or <a class="drug drug_general" data-topicid="121885" href="/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a> are alternatives. Polymyxins are typically reserved for infections when there are no other options. </p><p>Our recommendations are largely consistent with the Infectious Diseases Society of America (IDSA) guidance on management of antimicrobial-resistant gram-negative infections, which also favor monotherapy if in vitro susceptibility to one of these agents is confirmed and list <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, and <a class="drug drug_general" data-topicid="121885" href="/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a> as preferred treatment options for difficult-to-treat <em>P. aeruginosa</em> infections [<a href="#rid70">70</a>]. <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">Cefiderocol</a> is another preferred agent for urinary tract infections in the IDSA guidance, but for infections outside the urinary tract, it is an alternative agent reserved for patients who cannot use other options. European guidelines generally match IDSA guidance, except ceftolozane-tazobactam is the only preferred agent in the European guidelines, which consider the other regimens to have insufficient evidence [<a href="#rid71">71</a>].</p><p class="headingAnchor" id="H1288474731"><span class="h3">Preferred agents</span><span class="headingEndMark"> — </span>For infections resistant to first-line agents, we suggest one of the following antibiotics, if available. Dosages are listed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p>For patients who were recently treated with one of these agents and present with a sepsis-like syndrome, we suggest choosing a different novel agent, at least until culture and susceptibility data are available. If <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> was used previously, we suggest also avoiding <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> due to cross-resistance between these agents. (See <a class="local">'Emergence of resistance to novel agents'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a> – Several observational studies have described successful use of ceftolozane-tazobactam [<a href="#rid72">72-75</a>]. In a retrospective study of 200 patients with multidrug-resist<em>ant P. aeruginosa</em> infections (52 percent with ventilator-associated pneumonia), receipt of ceftolozane-tazobactam was associated with higher rates of clinical cure (adjusted odds ratio [aOR] 2.6) and lower rates of acute kidney injury (aOR 0.8) compared with aminoglycoside or polymyxin-containing regimens; in-hospital mortality was no different [<a href="#rid75">75</a>]. In another study of 205 patients, ceftolozane-tazobactam was associated with clinical success in 74 percent; receiving ceftolozane-tazobactam earlier, within four days of culture results, was associated with better outcomes [<a href="#rid72">72</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a> – In a pooled analysis of results from randomized trials of patients with ceftazidime-resistant infections, ceftazidime-avibactam resulted in comparable clinical cures compared with the best-available therapy (usually a carbapenem); among 56 patients with <em>P. aeruginosa</em> treated with ceftazidime-avibactam in this study, the microbiologic response rate was 57 percent [<a href="#rid76">76</a>].</p><p></p><p>There are no data comparing the two agents directly. <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">Ceftolozane-tazobactam</a> is generally regarded as having more potent activity [<a href="#rid77">77</a>], but the choice between them should depend on the susceptibility pattern of the infecting isolate, as there are regional differences in susceptibility to the two agents. In a study of 42 isolates of non-carbapenemase-producing, carbapenem-resistant <em>P. aeruginosa</em> isolates from South Korean hospitals, 95 percent were susceptible to ceftolozane-tazobactam compared with 71 percent to <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> [<a href="#rid78">78</a>]. In contrast, in a study of isolates from the Middle East, where many of the isolates produced class A, C, and D beta-lactamases (which are inhibited by avibactam but not tazobactam), susceptibility rates were slightly higher to ceftazidime-avibactam [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H152730777"><span class="h3">Alternative agents</span><span class="headingEndMark"> — </span>If one of the preferred agents is not an option, <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a> and <a class="drug drug_general" data-topicid="121885" href="/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a> are novel agents that are acceptable alternatives. There is even less clinical experience with these agents. Dosages are listed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">Cefiderocol</a> – Most carbapenem-resistant isolates remain susceptible to cefiderocol, a novel siderophore cephalosporin [<a href="#rid10">10,80</a>]. In a trial of patients with complicated urinary tract infection, cefiderocol resulted in similar clinical and microbiologic cure rates for the few infections caused by <em>P. aeruginosa </em>compared with <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>; however, the study did not include carbapenem-resistant organisms [<a href="#rid38">38</a>]. The IDSA does not list cefiderocol as a preferred agent for infections outside of the urinary tract because it was associated with higher all-cause mortality compared with best available therapy (typically a polymyxin-containing regimen) for non-urinary tract infections caused by carbapenem-resistant bacteria; only 28 <em>P. aeruginosa</em> infections were included in the trial [<a href="#rid40">40,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="121885" href="/d/drug information/121885.html" rel="external">Imipenem-cilastatin-relebactam</a> – The addition of relebactam to imipenem-cilastatin restores activity against some <em>P. aeruginosa</em> isolates that are resistant to <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>. In a trial of patients with serious infection caused by imipenem-resistant organisms (70 percent of which were <em>P. aeruginosa</em>), there was a trend toward lower 28-day mortality rates with imipenem-cilastatin-relebactam compared with imipenem-cilastatin plus <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H2066985490"><span class="h3">Other agents</span><span class="headingEndMark"> — </span>If the above antibiotics are not available, effective options are limited. Dosages are listed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polymyxins</strong> – We only use polymyxins (<a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a> or <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a>) when no other options exist because of their potential for toxicity. If a polymyxin is used for therapy of infections other than cystitis, we typically use it with a second susceptible agent. For cystitis, colistin can be used as monotherapy, but polymyxin B should be avoided due to suboptimal urinary levels. Care must be taken when dosing colistin and polymyxin B, as formulations differ between United States and European products, and each has distinct dosing recommendations. (See  <a class="medical medical_review" href="/d/html/486.html" rel="external">"Polymyxins: An overview", section on 'Dosing and administration'</a>.)</p><p></p><p class="bulletIndent1">Polymyxins have been used with some success in observational studies and case series [<a href="#rid83">83-89</a>]. As an example, in a study of 22 patients with metallo-beta-lactamase-producing <em>Pseudomonas</em> infections who were treated with intravenous <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a>, 67 percent had a partial or complete response [<a href="#rid87">87</a>]. However, two-thirds developed at least mild nephrotoxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aminoglycosides</strong> – We typically do not use these agents as monotherapy for infections other than cystitis. For uncomplicated blood stream infections for which source control has been achieved, we sometimes use aminoglycosides when no other options are possible due to resistance or lack of availability. Careful monitoring of dosing, drug levels, and side effects should be assured in these cases. More information regarding the role of aminoglycosides is discussed above. (See <a class="local">'Role of aminoglycosides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotics that should not be used</strong> – Many novel antibiotics are not recommended for <em>Pseudomonas </em>infections due to high probability of resistance. These include <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a>, <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, and <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>. <a class="drug drug_general" data-topicid="114672" href="/d/drug information/114672.html" rel="external">Meropenem-vaborbactam</a> does not provide additional activity beyond <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> alone and is not active against meropenem-resistant isolates.</p><p></p><p class="headingAnchor" id="H3009851088"><span class="h3">Adjunctive inhaled antibiotics for pneumonia</span><span class="headingEndMark"> — </span>Although we do not routinely use inhaled antibiotics for the treatment of <em>P. aeruginosa</em> pneumonia susceptible for first-line agents, they may be effective as an adjunct to intravenous therapy in cases of infection due to multidrug-resistant strains. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia", section on 'Inhaled antibiotics for selected patients'</a>.)</p><p class="headingAnchor" id="H3612994584"><span class="h2">Emergence of resistance to novel agents</span><span class="headingEndMark"> — </span>Reports of emergence of resistance during or following therapy with novel agents are accumulating. The frequency of emergent resistance with these agents is difficult to ascertain due to limited data, most of which is extrapolated from treatment trials.</p><p>Small observational studies have reported resistance to <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> in 50 to 100 percent of patients who had positive cultures after being treated with the agent for at least 72 hours [<a href="#rid90">90,91</a>]. Of additional concern, cross-resistance between ceftolozane-tazobactam and <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> occurs because of similar mechanisms of resistance; in one study of 28 patients treated with ceftolozane-tazobactam, ceftazidime-avibactam resistance occurred in 86 percent of isolates previously susceptible to the agent [<a href="#rid91">91</a>]. </p><p>Reports of resistance after exposure to imipenem-relebactam or <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a> for pseudomonal infections are less common, but these agents are newer than <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> and <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>. Concern is warranted for all novel agents until further data emerge.</p><p class="headingAnchor" id="H2931679251"><span class="h2">Pandrug-resistant isolates</span><span class="headingEndMark"> — </span>Isolates that are resistant to first-line agents, novel beta-lactam-beta-lactamase inhibitors, and <a class="drug drug_general" data-topicid="126182" href="/d/drug information/126182.html" rel="external">cefiderocol</a> present particular therapeutic challenges. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> – For extensively resistant organisms, we use combination therapy with the agent that has the lowest MIC combined with either a sensitive aminoglycoside or <a class="drug drug_general" data-topicid="9790" href="/d/drug information/9790.html" rel="external">polymyxin B</a>, if possible [<a href="#rid24">24</a>]. </p><p></p><p class="bulletIndent1">For isolates resistant to all available antibiotics, some clinicians have used combinations of drugs that separately have little or no activity against the isolate [<a href="#rid92">92,93</a>]. There are minimal clinical data to support such combination therapy. If combination therapy is used for treatment of organisms with extreme or unusual multidrug resistance patterns, it should be done in consultation with an expert in treating such infections whenever possible.</p><p></p><p class="bulletIndent1">In a single clinical series of 64 patients with nosocomial pulmonary infections due to a highly resistant <em>P. aeruginosa</em> susceptible only to <a class="drug drug_general" data-topicid="8718" href="/d/drug information/8718.html" rel="external">colistin</a>, treatment with the combination of <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a> and <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> was associated with survival in 44 (69 percent) [<a href="#rid94">94</a>]. These agents were the least inactive antibiotics by MIC determination and had demonstrated synergy in vitro. Dual beta-lactam therapy [<a href="#rid95">95</a>] and combinations with <a class="drug drug_general" data-topicid="8477" href="/d/drug information/8477.html" rel="external">fosfomycin</a> [<a href="#rid96">96-98</a>] have also been described with some success.</p><p></p><p class="bulletIndent1">Combination regimens of other common antibiotics have been found to have enhanced activity against multidrug-resistant <em>P. aeruginosa</em> in vitro, but overall clinical data are extremely limited [<a href="#rid93">93,99-107</a>]. The mechanisms for the enhanced activity are unknown for most combinations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational approaches</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Phage therapy</strong> – Phage therapy has been evaluated for P. aeruginosa endovascular infections in case reports and animal studies [<a href="#rid108">108,109</a>]. The frequency and significance of acquired resistance to phage treatment are uncertain issues. (See  <a class="medical medical_review" href="/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antibiotics in development</strong> – Murepavadin is a promising antibacterial agent with potent activity against carbapenem-resistant and colistin-resistant <em>P. aeruginosa </em>[<a href="#rid110">110</a>]. It is being evaluated for <em>P. aeruginosa</em> ventilator-associated pneumonia [<a href="#rid111">111</a>]. </p><p></p><p class="headingAnchor" id="H371761289"><span class="h1">TREATMENT IN CHILDREN</span><span class="headingEndMark"> — </span>The general principles of antipseudomonal therapy in children are similar to those in adults, with the main exception that antimicrobial dosing is weight based. Additionally, the use of fluoroquinolones in children warrants specific consideration. </p><p>There have been reports of tendon inflammation and/or rupture with fluoroquinolone antibiotics in all ages; risk may be increased with concurrent steroids and in solid organ transplant recipients. In some pediatric studies, an increased risk of reversible adverse events involving joints or surrounding tissues, often due to reports of arthralgia, has been observed [<a href="#rid112">112,113</a>]. However, no compelling published evidence supports the occurrence of sustained injury to developing bones or joints in children treated with available fluoroquinolone agents [<a href="#rid114">114,115</a>]. Use of a fluoroquinolone is a consideration for gram-negative infections caused by isolates susceptible to these agents. Specifically, this includes treatment for infections when caused by <em>P. aeruginosa</em>, including chronic suppurative otitis media, malignant otitis externa, bony infections associated with nail wound puncture, and complicated urinary tract infection. The risks and benefits should be considered if a fluoroquinolone is prescribed in a child younger than 18 years of age. (See  <a class="medical medical_review" href="/d/html/91002.html" rel="external">"Chronic suppurative otitis media (CSOM): Treatment, complications, and prevention", section on 'Treatment failure'</a> and  <a class="medical medical_review" href="/d/html/3413.html" rel="external">"Malignant (necrotizing) external otitis"</a> and  <a class="medical medical_review" href="/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections", section on 'Infection following nail puncture'</a> and  <a class="medical medical_review" href="/d/html/5991.html" rel="external">"Urinary tract infections in infants older than one month and children less than two years: Acute management, imaging, and prognosis"</a> and  <a class="medical medical_review" href="/d/html/490.html" rel="external">"Fluoroquinolones", section on 'Children'</a>.)</p><p class="headingAnchor" id="H371766674"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic resistance</strong> – <em>Pseudomonas aeruginosa</em> is intrinsically resistant to a number of antibiotics and can acquire resistance during therapy. These features limit the choices of antibiotics for <em>P. aeruginosa</em>. (See <a class="local">'Antimicrobial resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic dosing strategies</strong> – Certain agents require higher dosing when used for presumptive or known <em>P. aeruginosa</em> infections, and prolonged infusions optimizes pharmacokinetics for some agents (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>). (See <a class="local">'Dosing strategies'</a> above and  <a class="medical medical_review" href="/d/html/97446.html" rel="external">"Prolonged infusions of beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>First-line antibiotics</strong> – Multiple antibiotics from different classes are available to treat pseudomonal infections. (See <a class="local">'Antibiotics with antipseudomonal activity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intravenous options</strong> – Intravenous options include <a class="drug drug_general" data-topicid="9777" href="/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9047" href="/d/drug information/9047.html" rel="external">aztreonam</a>, fluoroquinolones, and carbapenems. Aminoglycosides are generally not used as single agents because of inadequate clinical efficacy at most sites. Doses are discussed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>). (See <a class="local">'Antibiotics with antipseudomonal activity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oral options</strong> – Fluoroquinolones are the only class of antibiotics with an oral formulation that is reliably active against <em>P. aeruginosa</em>. Doses are discussed in the table (<a class="graphic graphic_table graphicRef91115" href="/d/graphic/91115.html" rel="external">table 2</a>). (See <a class="local">'Oral antibiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination therapy</strong> – There is no convincing clinical evidence that using two active agents instead of one leads to improved outcomes. However, using two agents for empiric therapy may increase the likelihood that an active agent will be used for a potentially resistant organism, and this, in turn, is associated with better outcomes for serious infections. (See <a class="local">'Role of combination antimicrobial therapy'</a> above.) </p><p></p><p class="bulletIndent1">For patients who have sepsis or septic shock, have neutropenia and bacteremia, have severe burns, or are in a setting where the incidence of resistance to the chosen antibiotic class is high (eg, &gt;10 to 15 percent), we suggest empiric therapy with a combination of two antipseudomonal agents (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The two agents should be from different antibiotic classes (eg, a beta-lactam with an aminoglycoside or a quinolone). (See <a class="local">'Indications'</a> above and <a class="local">'Selection of agents'</a> above.)</p><p></p><p class="bulletIndent1">For patients without any of these additional risk factors for mortality or resistant organisms, we suggest empiric treatment with a single antipseudomonal agent (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Directed therapy</strong> – Once antimicrobial susceptibility data are available, we typically use a single active antipseudomonal agent. The rare exceptions when we might continue combination include neutropenia and bacteremia, endocarditis, failure to improve on therapy, and multidrug resistance. (See <a class="local">'Directed combination therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of multidrug-resistant organisms</strong> – For <em>P. aeruginosa</em> isolates resistant to first-line agents (including carbapenems), we suggest <a class="drug drug_general" data-topicid="98763" href="/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> or <a class="drug drug_general" data-topicid="100152" href="/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, as long as the isolate is susceptible (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Multidrug-resistant <em>P. aeruginosa</em> should be managed with the assistance of an expert in the treatment of such infections. (See <a class="local">'Management of multidrug-resistant organisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment of children</strong> – The general principles of antipseudomonal therapy in children are similar to those in adults, with the main exception that antimicrobial dosing is weight based. (See <a class="local">'Treatment in children'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 2011; 86:250.</a></li><li><a class="nounderline abstract_t">Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268.</a></li><li><a class="nounderline abstract_t">Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol 2016; 37:1288.</a></li><li><a class="nounderline abstract_t">Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med 2020; 382:1309.</a></li><li><a class="nounderline abstract_t">Rosenthal VD, Al-Abdely HM, El-Kholy AA, et al. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module. Am J Infect Control 2016; 44:1495.</a></li><li><a class="nounderline abstract_t">Thaden JT, Park LP, Maskarinec SA, et al. Increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa as compared to other bacteria: Results of a 13-year prospective cohort study. Antimicrob Agents Chemother 2017.</a></li><li><a class="nounderline abstract_t">Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50:43.</a></li><li><a class="nounderline abstract_t">Nakamura A, Miyake K, Misawa S, et al. Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect 2013; 83:153.</a></li><li><a class="nounderline abstract_t">Tartof SY, Kuntz JL, Chen LH, et al. Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection. JAMA Netw Open 2018; 1:e183927.</a></li><li class="breakAll">Health Alert Network. Outbreak of extensively drug-resistant Pseudomonas aeruginosa associated with artificial tears. Centers for Disease Control and Prevention. Feb 1, 2023. Available at: https://emergency.cdc.gov/han/2023/han00485.asp (Accessed on February 02, 2023).</li><li><a class="nounderline abstract_t">Seki M, Machida H, Yamagishi Y, et al. Nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa caused by damaged transesophageal echocardiogram probe used in cardiovascular surgical operations. J Infect Chemother 2013; 19:677.</a></li><li><a class="nounderline abstract_t">Pagani L, Colinon C, Migliavacca R, et al. Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase. J Clin Microbiol 2005; 43:3824.</a></li><li><a class="nounderline abstract_t">Catho G, Martischang R, Boroli F, et al. Outbreak of Pseudomonas aeruginosa producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care. Crit Care 2021; 25:301.</a></li><li><a class="nounderline abstract_t">Mudau M, Jacobson R, Minenza N, et al. Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African Academic Hospital. PLoS One 2013; 8:e55985.</a></li><li><a class="nounderline abstract_t">Bilavsky E, Pfeffer I, Tarabeia J, et al. Outbreak of multidrug-resistant Pseudomonas aeruginosa infection following urodynamic studies traced to contaminated transducer. J Hosp Infect 2013; 83:344.</a></li><li><a class="nounderline abstract_t">Fraser TG, Reiner S, Malczynski M, et al. Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangiopancreatography: failure of routine endoscope cultures to prevent an outbreak. Infect Control Hosp Epidemiol 2004; 25:856.</a></li><li><a class="nounderline abstract_t">Tuon FF, Gortz LW, Rocha JL. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. Braz J Infect Dis 2012; 16:351.</a></li><li><a class="nounderline abstract_t">Cohen MJ, Block CS, Moses AE, Nir-Paz R. Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance. Clin Microbiol Infect 2014; 20:O188.</a></li><li><a class="nounderline abstract_t">Djordjevic Z, Folic M, Ruzic Zecevic D, et al. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia. J Infect Dev Ctries 2013; 7:686.</a></li><li><a class="nounderline abstract_t">Anderson DJ, Miller B, Marfatia R, Drew R. Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation. Infect Control Hosp Epidemiol 2012; 33:589.</a></li><li><a class="nounderline abstract_t">Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43:1379.</a></li><li><a class="nounderline abstract_t">Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6:52.</a></li><li><a class="nounderline abstract_t">Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005; 11 Suppl 4:17.</a></li><li class="breakAll">Infectious Diseases Society of America. IDSA guidance on the treatment of antimicrobial-resistant gram-negative infections: Version 1.0. https://www.idsociety.org/practice-guideline/amr-guidance/#toc-1 (Accessed on July 06, 2022).</li><li><a class="nounderline abstract_t">Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.</a></li><li><a class="nounderline abstract_t">Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56:2129.</a></li><li><a class="nounderline abstract_t">Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003; 43:1116.</a></li><li><a class="nounderline abstract_t">Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089.</a></li><li><a class="nounderline abstract_t">Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272.</a></li><li><a class="nounderline abstract_t">Pillar CM, Torres MK, Brown NP, et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52:4388.</a></li><li><a class="nounderline abstract_t">Phe K, Bowers DR, Babic JT, Tam VH. Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia. Diagn Microbiol Infect Dis 2019; 93:346.</a></li><li><a class="nounderline abstract_t">Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 2015; 385:1949.</a></li><li><a class="nounderline abstract_t">Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462.</a></li><li><a class="nounderline abstract_t">Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16:661.</a></li><li><a class="nounderline abstract_t">Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis 2016; 62:1380.</a></li><li><a class="nounderline abstract_t">Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program. Clin Infect Dis 2016; 63:754.</a></li><li><a class="nounderline abstract_t">Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 2018; 18:285.</a></li><li><a class="nounderline abstract_t">Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018; 18:1319.</a></li><li class="breakAll">United States National Institutes of Health. Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens (APEKS-NP). https://clinicaltrials.gov/ct2/show/NCT03032380 (Accessed on January 07, 2020).</li><li><a class="nounderline abstract_t">Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 2021; 21:226.</a></li><li><a class="nounderline abstract_t">Sader HS, Castanheira M, Mendes RE, et al. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Máiz L, Girón RM, Olveira C, et al. Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials. Expert Opin Pharmacother 2013; 14:1135.</a></li><li><a class="nounderline abstract_t">Paulsson M, Granrot A, Ahl J, et al. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012; 25:450.</a></li><li><a class="nounderline abstract_t">Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745.</a></li><li><a class="nounderline abstract_t">Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306.</a></li><li><a class="nounderline abstract_t">Park SY, Park HJ, Moon SM, et al. Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia. BMC Infect Dis 2012; 12:308.</a></li><li><a class="nounderline abstract_t">Bowers DR, Liew YX, Lye DC, et al. Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2013; 57:1270.</a></li><li><a class="nounderline abstract_t">El Solh AA, Alhajhusain A. Update on the treatment of Pseudomonas aeruginosa pneumonia. J Antimicrob Chemother 2009; 64:229.</a></li><li><a class="nounderline abstract_t">Deconinck L, Meybeck A, Patoz P, et al. Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Infect Dis (Lond) 2017; 49:396.</a></li><li><a class="nounderline abstract_t">Albasanz-Puig A, Durà-Miralles X, Laporte-Amargós J, et al. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia. Microorganisms 2022; 10.</a></li><li><a class="nounderline abstract_t">Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540.</a></li><li><a class="nounderline abstract_t">Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621.</a></li><li><a class="nounderline abstract_t">Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.</a></li><li><a class="nounderline abstract_t">Kuikka A, Valtonen VV. Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital. Eur J Clin Microbiol Infect Dis 1998; 17:701.</a></li><li><a class="nounderline abstract_t">Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127.</a></li><li><a class="nounderline abstract_t">Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis 1998; 2:211.</a></li><li><a class="nounderline abstract_t">Chamot E, Boffi El Amari E, Rohner P, Van Delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756.</a></li><li><a class="nounderline abstract_t">Pizzo PA, Hathorn JW, Hiemenz J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552.</a></li><li><a class="nounderline abstract_t">Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004; 328:668.</a></li><li><a class="nounderline abstract_t">Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519.</a></li><li><a class="nounderline abstract_t">Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents 2013; 41:301.</a></li><li><a class="nounderline abstract_t">Paul M, Leibovici L. Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia. Lancet Infect Dis 2005; 5:192.</a></li><li><a class="nounderline abstract_t">Peña C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57:208.</a></li><li><a class="nounderline abstract_t">McLaughlin FJ, Matthews WJ Jr, Strieder DJ, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo. J Infect Dis 1983; 147:559.</a></li><li><a class="nounderline abstract_t">Smith AL, Doershuk C, Goldmann D, et al. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999; 134:413.</a></li><li><a class="nounderline abstract_t">Michéa-Hamzehpour M, Pechère JC, Marchou B, Auckenthaler R. Combination therapy: a way to limit emergence of resistance? Am J Med 1986; 80:138.</a></li><li><a class="nounderline abstract_t">Michéa-Hamzehpour M, Auckenthaler R, Regamey P, Pechère JC. Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis. Antimicrob Agents Chemother 1987; 31:1803.</a></li><li><a class="nounderline abstract_t">Lister PD, Wolter DJ. Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa. Clin Infect Dis 2005; 40 Suppl 2:S105.</a></li><li class="breakAll">Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. https://www.idsociety.org/practice-guideline/amr-guidance/ (Accessed on October 12, 2020).</li><li><a class="nounderline abstract_t">Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28:521.</a></li><li><a class="nounderline abstract_t">Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study. Open Forum Infect Dis 2018; 5:ofy280.</a></li><li><a class="nounderline abstract_t">Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Clin Infect Dis 2017; 65:110.</a></li><li><a class="nounderline abstract_t">Munita JM, Aitken SL, Miller WR, et al. Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa. Clin Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis 2020; 71:304.</a></li><li><a class="nounderline abstract_t">Stone GG, Newell P, Gasink LB, et al. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother 2018; 73:2519.</a></li><li><a class="nounderline abstract_t">Moise P, DeRyke CA, Gonzalez M, et al. 1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation. Open Forum Infect Dis 2021; 7:S797.</a></li><li><a class="nounderline abstract_t">Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Sid Ahmed MA, Abdel Hadi H, Hassan AAI, et al. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. J Antimicrob Chemother 2019; 74:3497.</a></li><li><a class="nounderline abstract_t">Kazmierczak KM, Tsuji M, Wise MG, et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study). Int J Antimicrob Agents 2019; 53:177.</a></li><li class="breakAll">Shinongi Inc. FDA antimicrobial drugs advisory committee: Cefiderocol briefing document. Oct 16, 2019. https://www.fda.gov/media/131705/download (Accessed on October 12, 2020).</li><li><a class="nounderline abstract_t">Motsch J, Murta de Oliveira C, Stus V, et al. RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clin Infect Dis 2020; 70:1799.</a></li><li><a class="nounderline abstract_t">Furtado GH, d'Azevedo PA, Santos AF, et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30:315.</a></li><li><a class="nounderline abstract_t">Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33:1162.</a></li><li><a class="nounderline abstract_t">Rios FG, Luna CM, Maskin B, et al. Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 2007; 30:307.</a></li><li><a class="nounderline abstract_t">Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54:670.</a></li><li><a class="nounderline abstract_t">Sabuda DM, Laupland K, Pitout J, et al. Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa. Can J Infect Dis Med Microbiol 2008; 19:413.</a></li><li><a class="nounderline abstract_t">Levin AS, Barone AA, Penço J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008.</a></li><li><a class="nounderline abstract_t">Linden PK, Kusne S, Coley K, et al. Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 2003; 37:e154.</a></li><li><a class="nounderline abstract_t">Rubio AM, Kline EG, Jones CE, et al. In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. Antimicrob Agents Chemother 2021; 65.</a></li><li><a class="nounderline abstract_t">Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. Clin Infect Dis 2021; 73:e4599.</a></li><li><a class="nounderline abstract_t">Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2:S95.</a></li><li><a class="nounderline abstract_t">Kmeid JG, Youssef MM, Kanafani ZA, Kanj SS. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther 2013; 11:1355.</a></li><li><a class="nounderline abstract_t">Dubois V, Arpin C, Melon M, et al. Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance. J Clin Microbiol 2001; 39:2072.</a></li><li><a class="nounderline abstract_t">Jiao Y, Moya B, Chen MJ, et al. Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43:52.</a></li><li><a class="nounderline abstract_t">Apisarnthanarak A, Mundy LM. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents 2012; 39:271.</a></li><li><a class="nounderline abstract_t">Dinh A, Salomon J, Bru JP, Bernard L. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis 2012; 44:182.</a></li><li><a class="nounderline abstract_t">Zuravleff JJ, Yu VL, Yee RB. Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa. J Lab Clin Med 1983; 101:896.</a></li><li><a class="nounderline abstract_t">Urena MT, Barasoain I, Espinosa M, et al. Evaluation of different antibiotic actions combined with rifampicin. In vitro synergism against Pseudomonas and Proteus. Chemotherapy 1975; 21:82.</a></li><li><a class="nounderline abstract_t">Fish DN, Choi MK, Jung R. Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs. J Antimicrob Chemother 2002; 50:1045.</a></li><li><a class="nounderline abstract_t">Gunderson BW, Ibrahim KH, Hovde LB, et al. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003; 47:905.</a></li><li><a class="nounderline abstract_t">Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002; 46:1105.</a></li><li><a class="nounderline abstract_t">Timurkaynak F, Can F, Azap OK, et al. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units. Int J Antimicrob Agents 2006; 27:224.</a></li><li><a class="nounderline abstract_t">Asuphon O, Montakantikul P, Houngsaitong J, et al. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. Int J Infect Dis 2016; 50:23.</a></li><li><a class="nounderline abstract_t">Lingscheid T, Tobudic S, Poeppl W, et al. In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates. Pharmacology 2013; 91:214.</a></li><li><a class="nounderline abstract_t">Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31:695.</a></li><li><a class="nounderline abstract_t">Oechslin F, Piccardi P, Mancini S, et al. Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence. J Infect Dis 2017; 215:703.</a></li><li><a class="nounderline abstract_t">Chan BK, Turner PE, Kim S, et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018; 2018:60.</a></li><li class="breakAll">Locher HH, Chiquet P, Brun S, et al. P1836 Activity of murepavadin against colistin-resistant Pseudomonas aeruginosa clinical isolates. Abstract, 29th ECCMID, Amsterdam, Netherlands, April 2019. https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=68529 (Accessed on January 07, 2020).</li><li class="breakAll">United States National Institutes of Health. Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia. https://clinicaltrials.gov/ct2/show/NCT02096328 (Accessed on January 07, 2020).</li><li><a class="nounderline abstract_t">Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 2011; 96:874.</a></li><li><a class="nounderline abstract_t">Noel GJ, Bradley JS, Kauffman RE, et al. Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 2007; 26:879.</a></li><li><a class="nounderline abstract_t">Jackson MA, Schutze GE, COMMITTEE ON INFECTIOUS DISEASES. The Use of Systemic and Topical Fluoroquinolones. Pediatrics 2016; 138.</a></li><li class="breakAll">American Academy of Pediatrics. Antimicrobial agents and related therapy. In: Red Book: 2018-2021 Report of the Committee on Infectious Diseases, 31st ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Itasca, IL 2018. p.903.</li></ol></div><div id="topicVersionRevision">Topic 3135 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21364117" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21793988" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27573805" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32242356" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742143" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010-2015: Device-associated module.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28373189" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa as compared to other bacteria: Results of a 13-year prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377665" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23201400" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646267" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Development and Assessment of Risk Scores for Carbapenem and Extensiveβ-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646267" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Development and Assessment of Risk Scores for Carbapenem and Extensiveβ-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23292134" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa caused by damaged transesophageal echocardiogram probe used in cardiovascular surgical operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16081918" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nosocomial outbreak caused by multidrug-resistant Pseudomonas aeruginosa producing IMP-13 metallo-beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34412676" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Outbreak of Pseudomonas aeruginosa producing VIM carbapenemase in an intensive care unit and its termination by implementation of waterless patient care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23516393" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Outbreak of multi-drug resistant Pseudomonas aeruginosa bloodstream infection in the haematology unit of a South African Academic Hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23419597" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outbreak of multidrug-resistant Pseudomonas aeruginosa infection following urodynamic studies traced to contaminated transducer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15518029" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multidrug-resistant Pseudomonas aeruginosa cholangitis after endoscopic retrograde cholangiopancreatography: failure of routine endoscope cultures to prevent an outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22846123" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24102767" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24042106" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561714" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10348756" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16542460" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953020" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15953020" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205441" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22290984" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14517194" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18379232" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074314" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779357" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30522794" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Outcomes of empiric aminoglycoside monotherapy for Pseudomonas aeruginosa bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25931244" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25670823" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27107460" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962078" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27313268" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29254862" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509675" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509675" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058795" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28137811" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23586963" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110415" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763634" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Combination therapy for treatment of infections with gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12955633" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15793102" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23157735" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Impact of adequate empirical combination therapy on mortality from bacteremic Pseudomonas aeruginosa pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23263001" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Outcomes of appropriate empiric combination versus monotherapy for Pseudomonas aeruginosa bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19520717" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Update on the treatment of Pseudomonas aeruginosa pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28092204" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of combination therapy and early de-escalation on outcome of ventilator-associated pneumonia caused by Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35456784" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with Pseudomonas aeruginosa Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2816969" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3927867" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Pseudomonas bacteremia. Retrospective analysis of 410 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695690" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865983" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9145881" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9763504" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12936970" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3526155" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14996699" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15288826" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23410791" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : β-Lactam plus aminoglycoside or fluoroquinolone combination versusβ-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15792730" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Combination antibiotic therapy for Pseudomonas aeruginosa bacteraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23580739" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339649" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10190914" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3088999" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Combination therapy: a way to limit emergence of resistance?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3124739" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Resistance occurring after fluoroquinolone therapy of experimental Pseudomonas aeruginosa peritonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712098" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712098" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Levofloxacin-imipenem combination prevents the emergence of resistance among clinical isolates of Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34923128" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30488041" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29017262" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329350" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Multicenter Evaluation of Ceftolozane/Tazobactam for Serious Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31545346" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29912399" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : 1603. Comparison of Ceftolozane/Tazobactam, Ceftazidime/Avibactam, and Meropenem/Vaborbactam Activity Against P. aeruginosa: A Multicenter Evaluation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133568" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504587" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30395986" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30395986" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400759" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17631984" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17530220" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17504791" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Ventilator-associated pneumonia due to colistin susceptible-only microorganisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22322268" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436571" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Utilization of colistin for treatment of multidrug-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452626" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14614688" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33820773" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32881997" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16894522" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24168069" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Combination therapy for Gram-negative bacteria: what is the evidence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11376037" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Nosocomial outbreak due to a multiresistant strain of Pseudomonas aeruginosa P12: efficacy of cefepime-amikacin therapy and analysis of beta-lactam resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30988147" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Comparable Efficacy and Better Safety of Doubleβ-Lactam Combination Therapy versusβ‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24183799" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22236455" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22176655" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6406628" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Ticarcillin-tobramycin-rifampin: in vitro synergy of the triplet combination against Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/169107" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Evaluation of different antibiotic actions combined with rifampicin. In vitro synergism against Pseudomonas and Proteus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12461031" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Synergic activity of cephalosporins plus fluoroquinolones against Pseudomonas aeruginosa with resistance to one or both drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604520" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11897598" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16464562" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418581" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23548688" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : In vitro activity of doripenem plus fosfomycin against drug-resistant clinical blood isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21805292" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28007922" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588855" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Phage treatment of an aortic graft infected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588855" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Phage treatment of an aortic graft infected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588855" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Phage treatment of an aortic graft infected with Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21785119" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Ciprofloxacin safety in paediatrics: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901792" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27940800" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The Use of Systemic and Topical Fluoroquinolones.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
